Please assess the completion status of the following clinical trial:

Trial Title: Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years old with INCan histopathological diagnosis of Lung Cancer Stage III or IV~* ECOG score ≤ 2~* Candidates for first-line chemotherapy based 1 st Paclitaxel / cisplatin 200 mg/m2 and 75 every 3 weeks~* Signed informed consent (and ethical scientific committee No. (010/023 (IMO) (CB/618~Exclusion Criteria:~* Patients who withdraw their consent and not want to continue with the evaluation of the study~* Common cold or hay fever, recent dental procedure, evidence of gingival inflammation or infection or oral mucosa~* People diagnosed with epilepsy or some other neurological disorders associated~* Concomitant radiotherapy in head and neck.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- BASELINE (Type: None): Outpatients from National Cancer Institute with stage III and IV NSCLC candidates for 1 st line chemotherapy paclitaxel-cisplatin based agreeing to participate in the study

Based on this trial design, predict the completion outcome and termination type (if applicable).